I. Introduction. The area to which attention is directed in the following pages lies in the north-eastern corner of Forfarshire, and forms part of the singularly flat table-land of the South-eastern Highlands. It is essentially a moorland district, much covered with peat and heather, and is drained by two rivers, the North Esk and the South Esk. The rocks of which the area is composed consist principally of gneisses and schists; these are clearly seen in the craggy sides of the valleys through which the two Esks and their tributaries flow. Boulders of these rocks may be noticed in the rough walls by the roadside as one drives up the glens, and their intensely crystalline aspect is a most striking feature. A brief visit to the crags and the flat-topped moorland speedily convinces the observer that this crystalline aspect is one of the chief characteristics of the district. It is proposed to show in the present communication that this area contains several masses of intrusive rock which are probably connected underground, and that the highly crystalline character of the surrounding schists is mainly the result of thermometamorphism. II. Distribution And Mode Of Occurrence Of The Igneous Rocks . The normal condition of the intrusive rock is that of a slightly foliated granite, with two micas; but there are considerable variations from this type, both as regards structure and composition, as will be seen from the detailed descriptions that follow. It is met with in masses which vary greatly in size, and

No abstract

This report describes double-blind placebo-controlled trials of a new synthetic antirhinovirus drug, R61837, which showed it to be effective in suppressing colds in human volunteers challenged with rhinovirus type 9. In one trial, R61837 was given by intranasal spray six times a day, commencing 28 h before virus challenge; treatment continued for 4 days and one dose (total dose, 25 mg). This regimen suppressed symptoms until 48 h after medication ceased, at which time colds developed. In another trial, medication with R61837 commenced at 4 h before virus challenge and continued for a total of 6 days (total dose, 36 mg). The drug produced substantial reductions in both the mean daily clinical score and the mean daily nasal secretion weight compared with patients given the placebo. These differences reached statistical significance for 2 and 4 days, respectively. In a further trial, intranasal R61837 was not effective in treating colds even when given shortly after the onset of symptoms and in doses of up to 15 mg/day.

Two studies involving double-blind group comparative trials in human volunteers compared the effects of intranasal nedocromil sodium (2.6 mg active drug per nostril, q.i.d.) with placebo on clinical symptoms and performance impairment associated with the common cold. In the first study volunteers were challenged with rhinoviruses (RV9 and RV14), and in the second study with respiratory coronavirus. In both studies, active and placebo groups of volunteers were demographically similar. Infection rates in both groups were also similar. There were no withdrawals resulting from unusual symptoms related to either treatment. In the rhinovirus study (19, placebo; 20, nedocromil sodium) daily symptom scores and daily mean nasal secretion weights were significantly lower in the nedocromil sodium-treated group. In the coronavirus study (26, placebo; 27, nedocromil sodium) there was little difference in the severity of colds between the active and placebo-treated groups, but trends favoured nedocromil sodium. In both studies the impairment of performance in volunteers who developed a cold was significantly less in those treated with nedocromil sodium than in those treated with placebo.

No abstract